The evolving tale of immunomodulatory drugs and cereblon

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 5, 2014, Pages 538-541

  Holstein, S A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEREBLON; IMMUNOMODULATING AGENT; LENALIDOMIDE; PHTHALIMIDE; POMALIDOMIDE; REGULATOR PROTEIN; THALIDOMIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR IKZF1; TRANSCRIPTION FACTOR IKZF3; UNCLASSIFIED DRUG; CRBN PROTEIN, HUMAN; IKAROS TRANSCRIPTION FACTOR; IKZF1 PROTEIN, HUMAN; IKZF3 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; PEPTIDE HYDROLASE;

ARTICLE; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME DEGRADATION; HISTORY OF MEDICINE; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); ANIMAL; CHEMICALLY INDUCED; GENETICS; METABOLISM; MULTIPLE MYELOMA; VENOUS THROMBOEMBOLISM;

ANIMALS; HUMANS; IKAROS TRANSCRIPTION FACTOR; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; PEPTIDE HYDROLASES; VENOUS THROMBOEMBOLISM;

EID: 84908210840     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.168     Document Type: Article

References (5)

1. Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345-1350 (2010).
2. Zhu, Y. X. et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118, 4771-4779 (2011).
3. Zhu, Y. X. et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood 124, 536-545 (2014).
4. Krönke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301-305 (2014).
5. Lu, G. et al. The myeloma drug lenalidomide promotes the cereblondependent destruction of Ikaros proteins. Science 343, 305-309 (2014).